东亚ST(Dong-A ST)贫血生物类似药Darbecron在阿联酋上市，借Julphar拓展中东北非18国

Dong-A ST Launches Anemia Biosimilar Darbecron in UAE - Seoul Economic Daily
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
Dong-A ST's anemia treatment biosimilar "Dabecron" (ingredient name: darbepoetin alfa), launched in the United Arab Emirates. Dong-A ST plans to expand sales to 18 countries across the Middle East and North Africa in partnership with local pharmaceutical company Julphar. Photo courtesy of Dong-A ST
Dong-A ST (170900.KS) has launched its in-house developed anemia biosimilar in the United Arab Emirates, accelerating its push into the Middle East market. The company aims to build a new growth base in the Middle East and North Africa after expanding sales in Japan.
Dong-A ST said on the 12th that it has launched Darbecron, a second-generation anemia biosimilar whose active ingredient is darbepoetin alfa and which was developed under the code name DA-3880, in the UAE.
The launch marks Dong-A ST's first commercialization in the Middle East and North Africa (MENA) region. In November 2024, the company signed a licensing-out agreement with UAE drugmaker Julphar covering 18 countries in the Middle East and North Africa. Under the deal, Julphar handles local product approval and sales.
Julphar obtained approval for Darbecron in the UAE in June this year and began local sales. The two companies plan to expand approvals and sales to major countries across the Middle East and North Africa, starting with the UAE.
Darbecron treats anemia that occurs in patients with chronic kidney disease or those undergoing chemotherapy. It was developed based on darbepoetin alfa, which stimulates red blood cell production.
Dong-A ST is also increasing Darbecron sales in Japan. After signing a licensing-out agreement with Sanwa Kagaku Kenkyusho (SKK) in 2014, it received local manufacturing and marketing approval in 2019. In Japan, the drug is sold under the name Darbepoetin Alfa BS Injection Sanwa.
Japan sales rose about 62% to 26.7 billion won last year from 16.5 billion won in 2024. Dong-A ST sells or is developing Darbecron as a Nesp biosimilar in Japan, the Middle East and North Africa, and Turkey, while pursuing development as an Aranesp biosimilar in the United States and Europe.
"With the approval and launch of Darbecron in the UAE, we have laid the groundwork for expanding into the Middle East and North Africa market," a Dong-A ST official said. "We will work with local partners to increase the number of countries where the drug is sold, while pressing ahead without delay on development for entry into major markets such as the United States and Europe."
#
DongAST
#
Darbecron
#
Biosimilar
#
Anemia
#
UAE
#
Julphar
Original reporting by
Park Hong-yong
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
2:43
After the Fed's Rate Hike, Rethink Your Stock Portfolio
2:43
Most Read This Week
1
-
5
‹
›
1
Military Exemption Boasts Spark Push to Overhaul Athlete Rules
2
Eurozone Rules Out Rescue as France Debt Fears Spread
3
Samsung Quarterly Operating Profit Tops 107 Trillion Won, Beating Nvidia
4
AMRO Lifts Korea's 2026 Growth Forecast Again to 3.3%
5
China's TCL Passes Samsung in LCD TVs, Leads by 0.1 Point
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗